Literature DB >> 28838698

Pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists.

Sunho Lee1, Changhoon Kim1, Jihyae Ann1, Shivaji A Thorat1, Eunhye Kim2, Jongmi Park2, Sun Choi2, Peter M Blumberg3, Robert Frank-Foltyn4, Gregor Bahrenberg4, Hannelore Stockhausen4, Thomas Christoph4, Jeewoo Lee5.   

Abstract

A series of 1-substituted 3-(t-butyl/trifluoromethyl)pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonamidophenyl)propanamides were investigated for hTRPV1 antagonism. The structure activity relationship indicated that the 3-chlorophenyl group at the 1-position of pyrazole was the optimized hydrophobic group for antagonistic potency and the activity was stereospecific to the S-configuration, providing exceptionally potent antagonists 13S and 16S with Ki(CAP)=0.1nM. Particularly significant, 13S exhibited antagonism selective for capsaicin and NADA and not for low pH or elevated temperature. Both compounds also proved to be very potent antagonists for rTRPV1, blocking in vivo the hypothermic action of capsaicin, consistent with their in vitro mechanism. The docking study of compounds 13S and 16S in our hTRPV1 homology model indicated that the binding modes differed somewhat, with that of 13S more closely resembling that of GRT12360.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Molecular modeling; TRPV1 antagonist; Vanilloid receptor 1

Mesh:

Substances:

Year:  2017        PMID: 28838698      PMCID: PMC6988736          DOI: 10.1016/j.bmcl.2017.08.020

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  33 in total

1.  The capsaicin receptor: a heat-activated ion channel in the pain pathway.

Authors:  M J Caterina; M A Schumacher; M Tominaga; T A Rosen; J D Levine; D Julius
Journal:  Nature       Date:  1997-10-23       Impact factor: 49.962

Review 2.  Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).

Authors:  Yoonji Lee; Sunhye Hong; Minghua Cui; Pankaz K Sharma; Jeewoo Lee; Sun Choi
Journal:  Expert Opin Ther Pat       Date:  2015-03       Impact factor: 6.674

3.  Analgesic potential of TRPV1 antagonists.

Authors:  Philip R Kym; Michael E Kort; Charles W Hutchins
Journal:  Biochem Pharmacol       Date:  2009-03-05       Impact factor: 5.858

Review 4.  Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks.

Authors:  Gilbert Y Wong; Narender R Gavva
Journal:  Brain Res Rev       Date:  2008-12-25

Review 5.  Modulation of the TRPV1 channel: current clinical trials and recent patents with focus on neurological conditions.

Authors:  Luciano De Petrocellis; Aniello S Moriello
Journal:  Recent Pat CNS Drug Discov       Date:  2013-12

6.  The cloned capsaicin receptor integrates multiple pain-producing stimuli.

Authors:  M Tominaga; M J Caterina; A B Malmberg; T A Rosen; H Gilbert; K Skinner; B E Raumann; A I Basbaum; D Julius
Journal:  Neuron       Date:  1998-09       Impact factor: 17.173

7.  Specific binding of resiniferatoxin, an ultrapotent capsaicin analog, by dorsal root ganglion membranes.

Authors:  A Szallasi; P M Blumberg
Journal:  Brain Res       Date:  1990-07-30       Impact factor: 3.252

Review 8.  Multisteric TRPV1 nocisensor: a target for analgesics.

Authors:  János Szolcsányi; Zoltán Sándor
Journal:  Trends Pharmacol Sci       Date:  2012-10-12       Impact factor: 14.819

9.  2-(3-Fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists: structure activity relationships of the 2-oxy pyridine C-region.

Authors:  Shivaji A Thorat; Dong Wook Kang; HyungChul Ryu; Myeong Seop Kim; Ho Shin Kim; Jihyae Ann; Taehwan Ha; Sung-Eun Kim; Karam Son; Sun Choi; Peter M Blumberg; Robert Frank; Gregor Bahrenberg; Klaus Schiene; Thomas Christoph; Jeewoo Lee
Journal:  Eur J Med Chem       Date:  2013-04-11       Impact factor: 6.514

Review 10.  Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway.

Authors:  Martin J Gunthorpe; Boris A Chizh
Journal:  Drug Discov Today       Date:  2008-12-26       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.